The past year has seen some extraordinary activity in clinical amyotrophic lateral sclerosis (ALS) research. Two trials were completed, with negative results, but the discovery of novel ALS-associated genes, and body fluid and imaging biomarkers warrants cautious optimism. Here, we provide a snapshot of some of the main findings in 2014.
2014 saw the completion of two highly anticipated clinical trials in amyotrophic lateral sclerosis (ALS). 1, 2 The first one was a multistage, multicentre trial on ceftri axone. 1 Ceftriaxone was chosen on the basis of preclinical data from the SOD1 Gly93Ala mouse model of ALS, which indicated that cephalosporins enhance excitatory amino acid transporter 2 activity, delay disease onset and prolong survival. 1 Patients treated with ceftriaxone in phase I (pharmaco kinetics) and phase II (safety) sections of the trial showed slower decline in the revised Amyotrophic Lateral Sclerosis Functional Rating Scale than did patients receiving placebo. Alas, phase III (efficacy) failed to show a beneficial effect for the drug in primary endpoints of functional decline and survival. Nevertheless, the innova tive trial design of the study, incorporating early and late stage testing (with appro priate go-nogo decision points), offers a useful model for future ALS clinical trials to move candidate therapeutic agents along the drug development pipeline more rapidly and efficiently.
The second trial was a placebocontrolled phase II-III trial of olesoxime (cholest4en 3one, oxime; Trophos, France), a molecule with potential neuroprotective properties. Olesoxime was identified in an in vitro screen for compounds that protect motor neurons from death by trophic factor dep rivation. 2 This doubleblind, randomized, placebo controlled multicentre trial involved 512 patients with ALS across five European countries. Although the drug was found to be well tolerated by the patients, none of the primary or secondary end points were reached.
These negative clinical trials have led to substantial soulsearching among the ALS research community. Moving forward, the key questions centre on whether a better way to select agents to be brought forward for clinical trials can be found, and whether ALS clinical trial designs can be made more efficient. The first question is complex and beyond the scope of this article-instead, we will focus on growing efforts to develop reliable biomarkers for ALS.
Finding a biomarker that is specific to ALS, has excellent prognostic value, and is sufficiently sensitive to detect progression is challenging. There is, however, reason for cautious optimism as recent technological advances have enabled a more datadriven approach in the quest for a reliable ALS biomarker. The past year, in particular, has seen progress in a range of areas, includ ing development of molecular biomarkers (genes, proteins, metabolic products), neuro physiological biomarkers (measurement of upper and lower motor neuron involvement), neuropsychological biomarkers (quantifica tion of subtle cognitive impairment), and neuroimaging biomarkers (differentiation of ALS from disorders that mimic ALS; following the course of neurodegeneration).
During 2014, three novel ALSassociated genes were identified: MATR3, 3 CHCHD10, 4 and TUBA4A, 5 and more are on the way. These genes provide insight into potential pathogenetic mechanisms in ALS. MATR3, located in 5q31.3, encodes matrin 3 proteinwhich is a nuclear matrix protein bound to the inner nuclear membrane-and is involved in DNA repair and transcription, and RNA processing and transport.
3 CHCHD10, located in 22q11.23, encodes a coiledcoil helix-coiledcoil helix protein the function of which is still unknown. However, CHCHD10 belongs to a family of mitochondrial pro teins that are located in the intermembrane space; some of these proteins are involved in cristae integrity and mitochondrial fusion. 4 TUBA4A, located in 2q36.1, encodes tubulin alpha 4A protein. Functional analy ses revealed that mutant forms of TUBA4A destabilize the micro tubule network and diminish its repolymerization capability; these findings emphasize the role of cytoskel etal defects in ALS. 5 Overall, in approximately twothirds of familial ALS cases and 10% of apparently sporadic cases, a genetic cause is detectable; the rest of the aetiology remains unknown. 3 In theory, the detection of a muta tion in a patient with suspected ALS should represent a specific and sensitive diagnostic marker. The reality is different, as the patho genicity and penetrance of many variants in these genes are not fully determined; more over, some cases of ALS might be oligogenic, that is, the phenotype is determined by the interaction of more than one gene.
Other 'wet' biomarkers have also shown promise in ALS diagnostics. Serum levels of light chain neurofilaments-major structural proteins in neurons that are released follow ing neuronal damage-were recently shown to have >90% sensitivity and specificity for separating patients with ALS from healthy controls. 6 Moreover, the immunoreactivity to plasma light chain neurofilaments changes in relation to ALS clinical staging, indicating that this biomarker might be also be useful in monitoring disease progression. 6 The ratio between phosphorylated tau (ptau) and total tau (ttau) in cerebrospinal fluid is similarly reported to have >90% sensitivity and speci ficity for distinguishing ALS from patients with 4repeattau diseases (progressive supranuclear palsy and corticobasal degen eration); furthermore, the ptau:ttau ratio in patients with ALS correlated with clinical measures of disease severity. 7 Although these findings are promising, neither study com pared patients with ALS with patients with diseases that mimic ALS, such as primary lateral sclerosis, cervical myelopathy, or axonal polyneuropathies. Therefore, these studies do not provide definitive proof that light chain neurofilaments or tau can be used as reliable diagnostic tools. Furthermore, longitudinal studies are necessary to deter mine whether these biomarkers are useful as proxies of ALS progression.
Neuroimaging is another rapidly evolv ing field of ALS research, and is being driven by improvements in imaging techniques and data analysis. Brain MRI has pro vided remarkable insight into upper motor neuron degeneration and the involvement of extramotor areas, such as the prefrontal cortex and basal ganglia. In an innovative approach to the analysis of neuroimaging data, 29 patients with ALS and 30 healthy controls matched for age and sex under went multi modal brain MRI that included proton magnetic resonance spectroscopy (MRS) with spectral editing techniques to measure γaminobutyric acid, and diffusion tensor imaging (DTI) to measure frac tional aniso tropy of the corticospinal tract. 8 The diagnostic accuracy was markedly improved when the MRS data were com bined with the DTI data, as compared with use of only the DTI data.
Although there is growing optimism con cerning the use of imaging as a biomarker of progression, several obstacles remain. The most obvious-and perhaps the most difficult to overcome-is the high attrition rate among patients with ALS in neuroimaging studies: respiratory compromise in the later stages of disease means that patients cannot lie flat for the prolonged periods needed to complete these advanced imaging examinations. The second issue surrounds the availability and cost of installing these advanced imaging modalities outside of academic centres.
18 FFDG-PET could be an alternative to multimodal MRI. Two large independent studies have shown that PET has a >90% accuracy for differentiating ALS patients from healthy controls, 9, 10 and from patients with primary lateral sclerosis. 10 The most important clusters of discrimination were found bilaterally in the thalamus, primary motor cortex, striatum, prefrontal and lateral prefrontal cortex, and posterior cingulate. 
